Uveal Melanoma Clinical Trial
Official title:
A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.
Verified date | April 2021 |
Source | California Pacific Medical Center Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy. The investigators will explore this synergy with a feasibility study of 26 patients with uveal melanoma and hepatic metastases who will receive SirSpheres Yttrium-90 selective internal hepatic radiation followed by immunotherapy with the combination of ipilimumab and nivolumab.
Status | Active, not recruiting |
Enrollment | 26 |
Est. completion date | June 2023 |
Est. primary completion date | January 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Histologic diagnosis of metastatic uveal melanoma. 2. Patients must have measurable disease as defined by RECIST (see Section 6). 3. Patients must have liver metastasis 4. Patients must have no more than one prior systemic therapeutic regimen. This includes chemotherapy, biologic therapy, biochemotherapy, or investigational treatment. This does not include any therapies given in the adjuvant setting. No prior anti-CTLA4 therapy. Prior anti PD-1 or anti-PDL-1 antibody therapy is acceptable. 5. No concomitant therapy with any of the following: IL-2, interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids. 6. Patients with prior selective internal radiation are candidates are eligible as long as they are candidates for repeat procedures and they have demonstrated progressive disease. 7. Age = 18 years. 8. No known infection with HIV. Due to the mechanism of action of ipilimumab, activity and side effects in an immune compromised patient are unknown. 9. No active infection with Hepatitis B. 10. No active infection with Hepatitis C. 11. ECOG performance status 0 or 1. 12. Women must not be pregnant or breast-feeding due to unknown effects of treatments on the unborn fetus. All women of childbearing potential must have a blood test within 72 hours prior to randomization to rule out pregnancy. Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized. Sexually mature females who have not undergone a hysterectomy or who have not been postmenopausal naturally for at least 24 consecutive months (i.e., who have had menses at some time in the preceding 24 consecutive months) are considered to be of childbearing potential. Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g.,vasectomy) should be considered to be of childbearing potential. 13. Patients must have the following lab values obtained < 4 weeks prior to starting treatment: - WBC =2000/uL - ANC =1500/mcL - Platelets = 100,000/mcL - Hemoglobin = 8g/dL - Creatinine = 3.0 xULN - AST and ALT < 2.5 x ULN - Bilirubin = 2.0 x ULN, (except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL) - Albumin = 3g/dL Exclusion Criteria 1. Patients are excluded if they have liver tumor volume > 50% 2. Patients are excluded if they have active CNS metastases. Patients with history of CNS metastases must have MRI scans that show stability of brain metastases for 8 weeks. 3. Patients are excluded if they have a history of any other malignancy from which the patient has been disease-free for less than 2 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, or stage 1 or 2 cutaneous melanoma 4. Patients are excluded if they have a history of autoimmune disease, as follows: Patients with a history of inflammatory bowel disease are excluded from this study as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]). Patients with a history of Guillain-Barre Syndrome are excluded but myasthenia gravis or psoriasis is acceptable. 5. Patients are excluded for any underlying medical or psychiatric condition which, in the opinion of the investigator, will make treatment hazardous or obscure the interpretation of adverse events, such as a condition associated with frequent diarrhea. 6. Patients are excluded if they have a history of prior treatment with ipilimumab or CTLA-4 inhibitor. 7. Patients are excluded if they have any concurrent medical condition requiring the use of systemic steroids (the use of inhaled or topical steroids is permitted). 8. Patients are excluded if they have had prior hepatic arterial embolization therapy |
Country | Name | City | State |
---|---|---|---|
United States | University of Chicago | Chicago | Illinois |
United States | Jefferson Medical College of Thomas Jefferson University | Philadelphia | Pennsylvania |
United States | California Pacific Medical Center | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
David Minor, MD | California Pacific Medical Center, Jefferson Medical College of Thomas Jefferson University, University of Chicago |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | safety and tolerability of sequential selective internal radiation with Yttrium90 followed by immunotherapy with ipilimumab and nivolumab. | Determine the safety and tolerability of sequential selective internal radiation with Y90 followed by immunotherapy with ipilimumab and nivolumab in patients with uveal melanoma metastatic to the liver. Endpoints are CTAE determined grade 3-5 toxicities. | 5 years | |
Secondary | Preliminary clinical efficacy | co-endpoints for this measure will be RECIST response rate and PFS | 5 years | |
Secondary | immunological changes | Changes in peripheral blood lymphocyte counts | 5 years | |
Secondary | Correlation of tissue markers and response to immunotherapy | Study of archival tumor tissue for tumor mutations, PDL-1, PDL-2, others | 5 years | |
Secondary | Explore relationship of response to immunotherapy with tumor melanin | Correlate response with tumor production of melanin assessed by tumor density on MRI scans | 5years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04364230 -
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
|
Phase 1/Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT05542342 -
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
|
Phase 2 | |
Completed |
NCT02849145 -
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
|
N/A | |
Recruiting |
NCT01438658 -
Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
|
N/A | |
Not yet recruiting |
NCT00811200 -
Treatment Of Radiation Retinopathy Trial
|
Phase 2/Phase 3 | |
Completed |
NCT00121225 -
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
Phase 2 | |
Recruiting |
NCT05077280 -
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
|
Phase 2 | |
Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
Withdrawn |
NCT05482074 -
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
|
Phase 2 | |
Completed |
NCT04551352 -
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
|
Phase 1 | |
Not yet recruiting |
NCT06246149 -
Adjuvant Tebentafusp in High Risk Ocular Melanoma
|
Phase 3 | |
Completed |
NCT01955941 -
Vascular Response to Brachytherapy Using Functional OCT
|
||
Completed |
NCT00661622 -
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
|
Phase 2 | |
Recruiting |
NCT05502900 -
Adjuvant Melatonin for Uveal Melanoma
|
Phase 3 | |
Active, not recruiting |
NCT03070392 -
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
|
Phase 2 | |
Recruiting |
NCT06284512 -
Uveal Melanoma - Comparative Study
|
||
Recruiting |
NCT05524935 -
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
|
Phase 2 | |
Not yet recruiting |
NCT06073548 -
Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
|
||
Recruiting |
NCT06075589 -
Psychoeducation for Uveal Melanoma
|